WESTFORD, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO - News) today announced the pricing of its initial public offering of 5,000,000 shares of its Class A common stock at a price to the public of $15.00 per share. Of the 5,000,000 shares being sold in the offering, 4,000,000 shares are being sold by Cynosure and 1,000,000 shares are being sold by a wholly owned subsidiary of El.En. S.p.A., Cynosure's majority stockholder. In addition, Cynosure has granted to the underwriters a 30-day over-allotment option to purchase up to an additional 750,000 shares. Cynosure's Class A common stock is expected to begin trading on the Nasdaq National Market on December 9, 2005 under the symbol "CYNO."
The sole book-running underwriter for the offering is Citigroup Global Markets Inc. UBS Securities LLC, Jefferies & Company, Inc. and Needham & Company, LLC are acting as co-managers.
A copy of the final prospectus relating to this offering may be obtained by contacting Citigroup Corporate and Investment Banking, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220 (tel: 718-765-6732; fax: 718-765-6734).
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure's products incorporate a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.
COMPANY CONTACT: Timothy W. Baker EVP, Chief Financial Officer (978) 256-4200
Source: Cynosure, Inc.
